New CAR T-Cell therapy KITE-753 takes on standard treatment in lymphoma showdown
NCT ID NCT07479797
First seen Mar 26, 2026 · Last updated Jun 11, 2026 · Updated 12 times
Summary
This phase 3 study tests whether a new treatment called KITE-753 works better than the current CAR T-cell therapy, axicabtagene ciloleucel, for adults with large B-cell lymphoma that has come back or not responded after initial treatment. About 550 participants will be randomly assigned to receive one of the two therapies. The main goal is to see which treatment leads to more complete remissions at 6 months and longer event-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.